» Articles » PMID: 34790723

Berberine Attenuates Atherosclerotic Lesions and Hepatic Steatosis in ApoE Mice by Down-regulating PCSK9 Via ERK1/2 Pathway

Overview
Journal Ann Transl Med
Date 2021 Nov 18
PMID 34790723
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human's diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potential mechanisms of anti-atherosclerosis by BBR using ApoE mice.

Methods: The eight-week mice were divided into five groups: group 1 (wild type C57BL/6J mice with normal diet), group 2 (ApoE mice with normal diet), group 3 [ApoE mice with high-fat diet (HFD)], group 4 (ApoE mice with HFD, and treatment with low dose BBR of 50 mg/kg/d), and group 5 (ApoE mice with HFD, and treatment with high dose BBR of 100 mg/kg/d). After a 16-week treatment, the blood sample, aorta and liver were collected for lipid analysis, hematoxylin-eosin (HE) or oil red O staining, and Western blotting respectively. Besides, HepG2 Cells were cultured and treated with different concentrations of BBR (0, 5, 25 and 50 µg/mL) for 24 hours. Subsequently, cells were collected for real-time PCR or western blotting assays. Finally, the expression levels of PCSK9, LDL receptor (LDLR), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type I (SR-BI) were examined.

Results: Fifty mg/kg/d and 100 mg/kg/d of BBR decreased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) level. Moreover, BBR reduced aorta atherosclerotic plaque, and ameliorated lipid deposition in ApoE mice fed with HFD. Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells.

Conclusions: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway.

Citing Articles

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9.

Palumbo M, Ugolotti M, Zimetti F, Adorni M Atheroscler Plus. 2025; 59:39-53.

PMID: 39877131 PMC: 11773090. DOI: 10.1016/j.athplu.2024.12.004.


Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors.

Liou J, Chen P, Gao W, Yen J Tzu Chi Med J. 2024; 36(4):360-369.

PMID: 39421488 PMC: 11483095. DOI: 10.4103/tcmj.tcmj_46_24.


Berberine Inhibits Ferroptosis and Stabilizes Atherosclerotic Plaque through NRF2/SLC7A11/GPX4 Pathway.

Wang T, Yu L, Zheng J, Han X, Jin B, Hua C Chin J Integr Med. 2024; 30(10):906-916.

PMID: 39167283 DOI: 10.1007/s11655-024-3666-z.


Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment.

Sun X, Jia X, Tan Z, Fan D, Chen M, Cui N Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065770 PMC: 11279631. DOI: 10.3390/ph17070919.


Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.

Ionita-Radu F, Patoni C, Nancoff A, Marin F, Gaman L, Bucurica A Int J Mol Sci. 2024; 25(8).

PMID: 38673787 PMC: 11050387. DOI: 10.3390/ijms25084201.


References
1.
Tarasiuk A, Pawlik L, Fichna J . Berberine as a potential therapeutic agent in the treatment of acute pancreatitis. Postepy Biochem. 2019; 65(3):224-230. DOI: 10.18388/pb.2019_278. View

2.
Caliceti C, Rizzo P, Ferrari R, Fortini F, Aquila G, Leoncini E . Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin. Nutr Metab Cardiovasc Dis. 2017; 27(6):552-563. DOI: 10.1016/j.numecd.2017.04.002. View

3.
Chong B, Murphy J, Kupper T, Fuhlbrigge R . E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J Immunol. 2004; 172(3):1575-81. DOI: 10.4049/jimmunol.172.3.1575. View

4.
Lupo M, Macchi C, Marchiano S, Cristofani R, Greco M, DallAcqua S . Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. Nutr Metab Cardiovasc Dis. 2019; 29(11):1245-1253. DOI: 10.1016/j.numecd.2019.06.001. View

5.
Wei S, Zhang M, Yu Y, Lan X, Yao F, Yan X . Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway. PLoS One. 2016; 11(3):e0152097. PMC: 4806913. DOI: 10.1371/journal.pone.0152097. View